NanoViricides (NYSE: NNVC) Hits Fresh 52-Week High — Ran Up Over 50% Since Our Last Spotlight. Could This Be the Start of Its Next Big Run? |
| | | NV-387 May be the Urgent Solution to America's Exploding Measles Crisis!
NNVC is Redefining Antiviral Treatment with Multiple Orphan Drug Opportunities that Unlock Multi-Billion-Dollar Markets. |
|
|
|---|
|
NanoViricides (NYSE: NNVC) has been on an absolute tear — recently notching a new 52-week high and surging more than 50% since we last reintroduced it to the Guy Stocks audience.
Momentum has clearly returned to this under-the-radar biotech, and with investor attention heating up, the big question now is: could this be just the beginning of NNVC's next major breakout run? Time will tell, but all signs point to renewed excitement in one of 2026's most talked-about biotech stories.
Check out TradingViews Technicals |
 |
As measles outbreaks surge across the U.S. and threaten global elimination status, NanoViricides (NYSE: NNVC) has a clinically validated antiviral drug, NV-387, ready for emergency use.
This breakthrough therapy is poised to reshape the antiviral drug landscape and address one of the world's most contagious viruses.
Measles Outbreaks – A Rapidly Escalating Crisis
The U.S. is facing resurgent measles outbreaks not seen in over 30 years:
- South Carolina: 30 confirmed cases in Upstate, spreading in Spartanburg County; mobile vaccine units deployed.
- Utah & Arizona: Over 100 confirmed cases, spreading beyond initial centers.
- Small towns near Las Vegas: 123 cases reported.
- Globally: Canada's elimination status is at risk, Israel reports tragic fatalities, and New Zealand braces for a repeat of the 2019 outbreak.
With vaccination gaps widening and virus strains evolving, NV-387 stands as the first clinically validated therapy capable of directly combating measles infections.
Why NV-387 Is a Game-Changer
NV-387 is revolutionary because it:
- Directly destroys viruses before they infect cells.
- Protects critical organs like the lungs from immune-mediated damage.
- Offers a broad-spectrum antiviral platform, capable of targeting measles, respiratory viruses, and biodefense threats.
With measles resurging and new viral threats emerging, the world urgently needs a safe, effective, and deployable antiviral therapy to save lives and prevent epidemics. The Technology Behind NV-387
- Based on TheraCour® nanomedicine technology, licensed exclusively by NanoViricides.
- NV-387's nano-polymer micelle technology binds and destroys viruses in the blood, preventing them from infecting cells.
- Uses a unique "Re-Infection Inhibition" mechanism: mimics cellular heparan-sulfate proteoglycans to trap viruses, engulfing and neutralizing them before infection occurs.
This highly selective approach makes NV-387 a broad-spectrum, revolutionary antiviral platform, not just a single-disease drug.
Beyond Measles – A Broad-Spectrum Antiviral Powerhouse
NNVC is developing NV-387 for for multiple respiratory viruses, epidemic threats, and biodefense applications, including:
- COVID-19
- Influenza & H5N1 Bird Flu
- RSV
- MPox & Smallpox
The company also advances NV-HHV-1 for Shingles and holds broad-spectrum licensing for HIV, Hepatitis, Rabies, Dengue, Ebola, and Herpes. NV-387 positions NNVC as a versatile antiviral powerhouse with global impact.
Clinical Proof – NV-387 Delivers
- 130% Increased Survival in Measles: In humanized animal models, survival improved from 7.4 days to 17 days.
- Lung Protection: Significantly reduced viral and immune-mediated lung damage.
- Phase I Safety: Completed with no reported adverse events; non-immunogenic, non-mutagenic, non-genotoxic.
- Patient-Friendly: Oral gummies dissolve easily without swallowing, ideal for patients with rashes.
Phase II Plans
NNVC is moving forward with a novel, adaptive Phase II clinical trial for NV-387 targeting Viral Acute/Severe Acute Respiratory Infections (V-ARI, V-SARI), with protocols already developed.
Additionally, NV-387 is under evaluation as a treatment for MPox in Africa, with preliminary approval from the Democratic Republic of Congo's regulatory agency ACOREP.
These studies may also support potential US FDA approval for Smallpox under the "Animal Rule," opening a market opportunity of approximately $1 billion over five years via the US Strategic National Stockpile.
Additionally Orphan Drug Designation (ODD) applications are being pursued for MPox, Smallpox, and Measles, offering seven years of market exclusivity, research tax benefits, waived FDA fees, and the potential for Priority Review Vouchers valued at over $150 million!
Dual-Track Rapid Clinical Development
NNVC is executing a dual-track, rapid clinical strategy:
- Track 1: NV-387 Phase II trial against MPox in Congo, ethically approved, with potential BARDA biodefense funding.
- Track 2: Adaptive "basket-type" trial in India targeting Influenza, RSV, and Coronaviruses, leveraging the same clinical framework. Start planned for Winter 2026, potentially leading to U.S. trials in 2027.
This strategy positions NV-387 for multi-billion-dollar market potential, including:
- $2.6B in RSV
- $4.6B in Influenza
- Biodefense applications in MPox and Smallpox
The Bottom Line – Why Pay Attention
- NNVC is a publicly traded, clinically advanced biotech with exclusive global licenses for multiple antiviral candidates.
- NV-387's proven safety, dual-action mechanism, and broad-spectrum potential make it ready for rapid market adoption.
- As measles returns to endemic status in the U.S. and respiratory viruses continue to threaten public health, NV-387 may become an essential therapeutic, creating immediate and urgent market demand.
NV-387 is not just a drug—it's a paradigm shift in antiviral therapy.
With groundbreaking clinical results, broad-spectrum applications, and multi-billion-dollar market potential, see why NanoViricides (NYSE: NNVC) is primed for explosive growth and could be the defining biotech story of 2026
Do your research! |
|
|---|
|
| | Disclaimer
We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Guy Stocks nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Guy Stocks. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Guy Stocks makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website.
Some of the content on this website contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which may be beyond a company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. It is hereby noted that forward-looking statements contained herein may include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results.
Generally, the information regarding a company profiled or discussed on this website is provided from public sources Guy Stocks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Guy Stocks has no obligation to update any of the information provided. Guy Stocks, its owners, officers, directors, contractors and employees are not responsible for errors and omissions.
From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. Guy Stocksencourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content.Guy Stocks, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Guy Stocks control, endorse, or guarantee any content found in such sites. Guy Stocks does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that Guy Stocks its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Guy Stocks, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Guy Stocks uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm.
Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions.
Income Disclaimer
Guy Stocks and Organized Noise LLC have been retained by Interactive Offers LLC to perform promotional and advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from Interactive Offers LLC.
Guy Stocks and Organized Noise LLC have received a payment of $6,000 from Interactive Offers LLC for a 1 day marketing campaign of NanoViricides, Inc. (NNVC) with a start date 11/5/25 which services include the issuance of this release and other opinions that we release concerning NanoViricides, Inc. (NNVC). Guy Stocks has not investigated the background of NanoViricides, Inc. (NNVC) or Interactive Offers LLC. Anyone viewing this newsletter should assume NanoViricides, Inc. (NNVC) and Interactive Offers LLC or affiliates of NanoViricides, Inc. (NNVC) and Interactive Offers LLC own shares of NanoViricides, Inc. (NNVC) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Guy Stocks and Organized Noise LLC have received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding NanoViricides, Inc. (NNVC).
1389 Center Dr Park City UT 84098 USA UNSUBSCRIBE
|
|
|---|
| | |
|
